基本信息

 侯鹏,男,1974年10月,第一附属医院内分泌科副主任,博士生导师,西安交通大学第九批“腾飞”特聘教授及第一批“青年拔尖人才”,陕西省中青年科技创新领军人才,陕西省肿瘤精准医学重点实验室副主任。2005年至2009年在美国约翰·霍普金斯大学医学院从事博士后研究,主要从事肿瘤遗传与表观遗传学的相关工作。20099月受聘西安交通大学第一附属医院,并获得光华基金资助(光华特聘教授),次年入选教育部新世纪优秀人才支持计划。近年来,课题组共获得国家自然科学基金19项、973子课题1项及其它省部级项目多项;共发表SCI论文150篇,被引用超过4500(数据来自Web of Science),H-index为33其中以第一及通讯作者发表SCI论文80,IF>10的论文9篇,IF >5的论文41篇,影响因子总计超过4201篇论文入选ESI高被引论文,归入其学术领域中最优秀的 1% 之列)。此外,申请及合作申请专利3项。

 

 
代表论文(*通讯作者)

1.       Yang Q, Jiang W, Hou P*. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019; Apr 2. [IF: 10.198]

2.       He W, Yan J, Wang L, Lei B, Hou P*, Lu W*, Ma PX*. A lanthanide-peptide-derived bacterium-like nanotheranostic with high tumor-targeting, -imaging and -killing properties. Biomaterials. 2019; 206:13-24. [IF: 10.273]

3.       Su X, Shen Z, Yang Q, Sui F, Pu J, Ma J, Ma S, Yao D, Ji M, Hou P*. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. Theranostics. 2019; 9(15):4461-4473. [IF: 8.063]

4.       Dang S, Zhou J, Chen Y, Chen P, Ji M, Shi B, Yang Q*, Hou P*. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene. 2019; 38(24):4804-4819. [IF: 6.634]

5.       Li H, Tian Z, Qu Y, Yang Q, Guan H, Shi B, Ji M*, Hou P*. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis. Oncogene. 2019; 38(3):345-359. [IF: 6.634]

6.       Wang N, Li Y, Wei J, Pu J, Liu R, Yang Q, Guan H, Shi B, Hou P*, Ji M*. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways. Thyroid. 2019; 29(3):378-394. [IF: 7.786]

7.       He W, Wang S, Yan J, Qu Y, Jin L, Sui F, Li Y, You W, Yang G, Yang Q, Ji M, Liu M, Shao Y, Ma PX*, Lu W*, Hou P*. Self-Assembly of Therapeutic Peptide into Stimuli-Responsive Clustered Nanohybrids for Cancer-Targeted Therapy. Adv Funct Mater. 2019; 1807736. [IF: 15.621]

8.       He W, Yan J, Sui F, Wang S, Su X, Qu Y, Yang Q, Guo H, Ji M, Lu W, Shao Y*, Hou P*. Turning a Luffa Protein into a Self-Assembled Biodegradable Nanoplatform for Multitargeted Cancer Therapy. ACS Nano. 2018;12(11):11664-11677. [IF: 13.903]

9.       Li Y, Yang Q, Guan H, Shi B, Ji M*, Hou P*. ZNF677 suppresses Akt phosphorylation and tumorigenesis in thyroid cancer. Cancer Res. 2018; 78:5216-5228. [IF: 9.13]

10.    He W, Yan J, Jiang W, li S, Qu Y, Niu F, Yan Y, Sui F, Wang S, Zhou Y, Jin L, Ji M, Ma PX, Liu M*, Lu W*, Hou P*. Peptide-Induced Self-Assembly of Therapeutics into a Well-Defined Nanoshell with Tumor-Triggered Shape and Charge Switch. Chem Mater. 2018; 30:7034-7046. [IF: 10.159]

11.    Bian Z, Yan J, Wang S, Li Y, Guo Y, Ma B, Guo H, Lei Z, Yin C, Zhou Y, Liu M, Tao K*, Hou P*, He W*. Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery. Theranostics. 2018; 8(19):5320-5335. [IF: 8.063]

12.    Li Y, Li X, Pu J, Yang Q, Guan H, Ji M, Shi B*, Chen M*, Hou P*. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer. Thyroid. 2018; 28(12): 1642-54. [IF: 7.786]

13.    Qu Y, Yang Q, Liu J, Shi B, Ji M, Li G*, Hou P*. c-Myc is required for BRAFV600E-induced epigenetic silencing by H3K27me3 in tumorigenesis. Theranostics. 2017; 7(8):2092-2107. [IF: 8.063]

14.    Yang Q and Hou P*. Targeting PFKFB3 in the Endothelium for Cancer Therapy. Trends Mol Med. 2017; 23(3):197-200. [IF: 11.028]

15.    Qu Y, Dang S, Wu K, Shao Y, Yang Q, Ji M, Shi B, Hou P*. TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer. 2014;135(4):1008-1010. [IF: 7.36]

16.    Qu Y, Shi L, Wang D, Zhang B, Yang Q, Ji M, Shi B, Hou P*. Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers. Int J Cancer. 2014;134(12):2993-2994. [IF: 7.36]

17.    Hou P, Liu D, Shan Y, Hu S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007; 13(4):1161-70. [IF: 10.2]

18.    Hou P, Liu D, Xing M*. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia. 2007; 21(10):2216-8. [IF: 10.023]

19.    Hou P, Chen Z, Ji M, He N, Lu Z*. Real-time PCR assay for ultrasensitive quantification of DNA-binding proteins. Clin Chem. 2007; 53(4):581-6. [IF: 8.636]

20.    Hou P, Ji M, Ge C, Shen J, Li S, He N, Lu Z*. Detection of methylation of human p16(Ink4a) gene 5'-CpG islands by electrochemical method coupled with linker-PCR. Nucleic Acids Res. 2003; 31(16):e92. [IF: 11.147]

 
 
主要学术任职
  1. Am J Cancer Res. (IF: 4.737)、World J Gastroenterol. (IF: 3.411)、临床医学研究与实践杂志和西安交通大学学报(医学版)编委
  2. 陕西省肿瘤联盟甲状腺癌专业委员会 副主任委员
  3. 陕西省国际医学促进会内分泌/遗传/代谢专业委员会 副主任委员
  4. 中华医学会内分泌分会 青年委员
  5. 中华医学会陕西省内分泌分会 委员
  6. 中华医学会内分泌分会“转化医学学组”成员
  7. 中国细胞生物学会青年委员会 委员
  8. 中国抗癌协会肿瘤代谢专业委员会 委员
  9. 陕西省抗癌协会生物样本库专业委员会 常务委员
  10. 陕西省抗癌协会肿瘤标志物专业委员会 常务委员
 
研究方向
1)肿瘤遗传与表观遗传学;2)肿瘤早期诊断与个体化治疗;2)肿瘤分子靶向治疗
 
联系方式
电话:029-85324749 (O)
 

欢迎报考!